|
2015 Conference Publication The Wau (weighted activity unit) effect: evaluating the cost of Drg (Diagnosis related group) codingTan, J. Y., Bennett, R., Power, J., Thompson, L., Hughes, B. and Lwin, Z. (2015). The Wau (weighted activity unit) effect: evaluating the cost of Drg (Diagnosis related group) coding. The Medical Oncology Group of Australia 2015 ASM, Pathways in Medical Oncology – The Path Less Travelled, Hobart, Australia, 5‐7 August 2015. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. |
|
2015 Journal Article An unusual recurrence of adenosquamous carcinoma of the lungPokharel, Khageshwor, Godbolt, David and Hughes, Brett G. M. (2015). An unusual recurrence of adenosquamous carcinoma of the lung. Cancer Treatment Communications, 4, 37-40. doi: 10.1016/j.ctrc.2015.03.006 |
|
2014 Journal Article First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung CancerSolomon, Benjamin J., Mok, Tony, Kim, Dong-Wan, Wu, Yi-Long, Nakagawa, Kazuhiko, Mekhail, Tarek, Felip, Enriqueta, Cappuzzo, Federico, Paolini, Jolanda, Usari, Tiziana, Iyer, Shrividya, Reisman, Arlene, Wilner, Keith D., Tursi, Jennifer, Blackhall, Fiona, Boyer, M., Ganju, V., Hughes, B., Pavlakis, N., Solomon, B., Varma, S., Berghmans, T., Canon, J-L, Demedts, I., Janssens, A., Louis, R., Pieters, T., Schallier, D., Surmont, V. ... Waqar, S. (2014). First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. New England Journal of Medicine, 371 (23), 2167-2177. doi: 10.1056/NEJMoa1408440 |
|
2014 Journal Article Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinomaFoote, M. C., McGrath, M., Guminski, A., Hughes, B. G. M., Meakin, J., Thomson, D., Zarate, D., Simpson, F. and Porceddu, S. V. (2014). Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Annals of Oncology, 25 (10), 2047-2052. doi: 10.1093/annonc/mdu368 |
|
2014 Journal Article Nutrition outcomes following implementation of validated swallowing and nutrition guidelines for patients with head and neck cancerBrown, Teresa, Ross, Lynda, Jones, Lee, Hughes, Brett and Banks, Merrilyn (2014). Nutrition outcomes following implementation of validated swallowing and nutrition guidelines for patients with head and neck cancer. Supportive Care in Cancer, 22 (9), 2381-2391. doi: 10.1007/s00520-014-2180-9 |
|
2014 Journal Article Protocol for a randomized controlled trial of early prophylactic feeding via gastrostomy versus standard care in high risk patients with head and neck cancerBrown, Teresa, Banks, Merrilyn, Hughes, Brett, Kenny, Lizbeth, Lin, Charles and Bauer, Judith (2014). Protocol for a randomized controlled trial of early prophylactic feeding via gastrostomy versus standard care in high risk patients with head and neck cancer. BMC Nursing, 13 (1) 17, 17.1-17.10. doi: 10.1186/1472-6955-13-17 |
|
2014 Journal Article The ENHANCES study-enhancing head and neck cancer patients' experiences of survivorship: study protocol for a randomized controlled trialTurner, Jane, Yates, Patsy, Kenny, Lizbeth, Gordon, Louisa G., Burmeister, Bryan, Thomson, Damien, Hughes, Brett, McCarthy, Alexandra L., Perry, Chris, Chan, Raymond J., Fraser, Alana, Skerman, Helen, Batstone, Martin and Carswell, Kathryn (2014). The ENHANCES study-enhancing head and neck cancer patients' experiences of survivorship: study protocol for a randomized controlled trial. Trials, 15 (1) 191. doi: 10.1186/1745-6215-15-191 |
|
2014 Journal Article Myocardial infarction secondary to 5-fluorouracil: not an absolute contraindication to rechallenge?Rateesh, Shruti, Luis, Sushil A., Luis, Chris R., Hughes, Brett and Nicolae, Mugur (2014). Myocardial infarction secondary to 5-fluorouracil: not an absolute contraindication to rechallenge?. International Journal of Cardiology, 172 (2), E331-E333. doi: 10.1016/j.ijcard.2013.12.274 |
|
2014 Journal Article Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imagingHughes, Brett, Mileshkin, Linda, Townley, Peter, Gitlitz, Barbara, Eaton, Keith, Mitchell, Paul, Hicks, Rodney, Wood, Katie, Amler, Lucas, Fine, Bernard M., Loecke, David and Pirzkall, Andrea (2014). Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging. Oncologist, 19 (2), 175-176. doi: 10.1634/theoncologist.2013-0026 |
|
2014 Conference Publication Single Agent Panitumumab in Patients With Incurable Cutaneous Squamous Cell Carcinoma: A Single-Center Phase 2 StudyPorceddu, S., Foote, M., McGrath, M., Guminski, A., Hughes, B., Meakin, J., Thomson, D., Thomson, D. and Simpson, F. (2014). Single Agent Panitumumab in Patients With Incurable Cutaneous Squamous Cell Carcinoma: A Single-Center Phase 2 Study. ELSEVIER SCIENCE INC. doi: 10.1016/j.ijrobp.2013.11.179 |
|
2013 Journal Article Validated swallowing and nutrition guidelines for patients with head and neck cancer: Identification of high-risk patients for proactive gastrostomyBrown, Teresa E., Spurgin, Ann-Louise, Ross, Lynda, Tripcony, Lee, Keller, Jacqui, Hughes, Brett G. M., Hodge, Rob, Walker, Quenten, Banks, Merrilyn, Kenny, Lizbeth Moira and Crombie, Jane (2013). Validated swallowing and nutrition guidelines for patients with head and neck cancer: Identification of high-risk patients for proactive gastrostomy. Head and Neck, 35 (10), 1385-1391. doi: 10.1002/hed.23146 |
|
2013 Journal Article A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced malignant pleural mesotheliomaNowak, Anna K., Brown, Chris, Millward, Michael J., Creaney, Jenette, Byrne, Michael J., Hughes, Brett, Kremmidiotis, Gabriel, Bibby, David C., Leske, Annabell F., Mitchell, Paul L. R., Pavlakis, Nick, Boyer, Michael and Stockler, Martin R. (2013). A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced malignant pleural mesothelioma. Lung Cancer, 81 (3), 422-427. doi: 10.1016/j.lungcan.2013.05.006 |
|
2013 Journal Article Comment on 'The efficacy and toxicity of gemcitabine, carboplatin and bevacizumab in metastatic breast cancer'Kitchen, D., O'Brien, M., Hughes, B., Gill, I., Rumbles, S., Ellis, P. and Stebbing, J. (2013). Comment on 'The efficacy and toxicity of gemcitabine, carboplatin and bevacizumab in metastatic breast cancer'. British Journal of Cancer, 109 (2), 526-528. doi: 10.1038/bjc.2013.279 |
|
2013 Journal Article Other novel molecular targets in non-small cell lung cancer: it's not all about EGFRCruikshank, Ross and Hughes, Brett (2013). Other novel molecular targets in non-small cell lung cancer: it's not all about EGFR. Cancer Forum, 37 (2), 170-174. |
|
2013 Journal Article Decreased hospital stay and significant cost savings after routine use of prophylactic gastrostomy for high-risk patients with head and neck cancer receiving chemoradiotherapy at a tertiary cancer institutionHughes, B. G. M., Jain, V. K., Brown, T., Spurgin, A. L., Hartnett, G., Keller, J., Tripcony, L., Appleyard, M. and Hodge, R. (2013). Decreased hospital stay and significant cost savings after routine use of prophylactic gastrostomy for high-risk patients with head and neck cancer receiving chemoradiotherapy at a tertiary cancer institution. Dysphagia, 28 (3). doi: 10.1007/s00455-013-9468-7 |
|
2013 Journal Article Decreased hospital stay and significant cost savings after routine use of prophylactic gastrostomy for high-risk patients with head and neck cancer receiving chemoradiotherapy at a tertiary cancer institutionHughes, Brett G. M., Jain, Vikram K., Brown, Teresa, Spurgin, Ann-Louise, Hartnett, Gemma, Keller, Jacqui, Tripcony, Lee, Appleyard, Mark and Hodge, Robert (2013). Decreased hospital stay and significant cost savings after routine use of prophylactic gastrostomy for high-risk patients with head and neck cancer receiving chemoradiotherapy at a tertiary cancer institution. Head and Neck, 35 (3), 436-442. doi: 10.1002/hed.22992 |
|
2013 Journal Article Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancerSavas, Peter, Hughes, Brett and Solomon, Benjamin (2013). Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. Journal of Thoracic Disease, 5 (5), S579-S592. doi: 10.3978/j.issn.2072-1439.2013.08.52 |
|
2013 Conference Publication Single agent panitumumab in patients with incurable cutaneous squamous cell carcinoma: A single centre phase II studyFoote, M., McGrath, M., Guminski, A., Hughes, B., Meakin, J., Thomson, D., Simpson, F. and Porceddu, S. (2013). Single agent panitumumab in patients with incurable cutaneous squamous cell carcinoma: A single centre phase II study. 17th ECCO / 38th ESMO / 32nd ESTRO European Cancer Congress on Reinforcing Multidisciplinarity, Amsterdam Netherlands, Sep 27-Oct 01, 2013. Oxford United Kingdom: Pergamon Press. doi: 10.1016/S0959-8049(13)70065-0 |
|
2012 Journal Article Challenging the distal-to-proximal cannulation technique for administration of anticancer therapies: A prospective cohort studyChan, Raymond Javan, Alexander, Alison, Bransdon, Maree, Webster, Joan, Hughes, Brett Gordon Maxwell, Brown, Leisa and Graham, Therese (2012). Challenging the distal-to-proximal cannulation technique for administration of anticancer therapies: A prospective cohort study. Cancer Nursing, 35 (5), E35-E40. doi: 10.1097/NCC.0b013e3182352916 |
|
2012 Conference Publication Pulmonary Embolism in Medical Oncology Patients: Symptomatic Versus IncidentalThaker, D. A., Blazak, J., Wyld, D., Steinke, K., Hughes, B. and Burge, M. (2012). Pulmonary Embolism in Medical Oncology Patients: Symptomatic Versus Incidental. HOBOKEN: WILEY-BLACKWELL. |
